India has developed BIRSA 101, its first indigenous CRISPR gene therapy for sickle cell disease, using a more precise ...

Two papers published in The New England Journal of Medicine highlight the potential of gene editing for treatment of sickle ...

The ethics of using safe gene therapies to improve the health and cognition of Down syndrome children and adults.

A CRISPR Therapy Just Cured A Disease From Inside The Body For The First Time. The Gene-Editing Era Officially Started Monday ...

Following its FDA-approved Casgevy therapy for sickle cell disease and beta thalassemia, CRISPR technology is now being tested in autoimmune disorders and early Down syndrome studies. CRISPR ...

As more products reach the market, therapy developers partner with researchers and regulators to deliver N-of-1 treatments to patients.

Intellia disclosed that a single dose of its gene editing treatment dramatically reduced swelling attacks in patients with ...

A child known publicly as Baby KJ was celebrated onstage at the twelfth Breakthrough Prize ceremony in Santa Monica last ...

Intellia Therapeutics has reported the first-ever phase 3 results with an in vivo gene-editing therapy, hereditary angioedema ...

CRSP eyes a Q1 beat as rising Casgevy uptake, improving sales outlook and a strong Earnings ESP set the stage ahead of results.

NEW YORK, NY – Two prominent biotechnology companies, Vertex Pharmaceuticals and CRISPR Therapeutics, both led by Indian American CEOs, have been named to TIME’s 2025 list of the 100 Most Influential ...

Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 10 best biotech stocks with highest upside potential. On April 2, Beam ...